Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

Trial Profile

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; BI 1206 (Primary) ; BI 1206 (Primary) ; Rituximab
  • Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors BioInvent International
  • Most Recent Events

    • 09 Feb 2024 According to a BioInvent International media release, company announced clinical supply agreement with AstraZeneca to support this study.Under the terms of the supply agreement, AstraZeneca will provide Calquenc for use in combination with BI-1206 and rituximab. This trial will be expanded to include the triplet arm.
    • 09 Feb 2024 Drug Calquence (acalabrutinib) has been added to study protocol for the treatment of patients with follicular lymphoma who have progressed or are refractory to rituximab, according to a BioInvent International media release.
    • 09 Feb 2024 According to a BioInvent International media release, the calquence expansion cohort is expected to enroll approximately 30 patients at sites in Sweden, Spain, the US, and Brazil.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top